Brief: Arctic Bioscience Q1 Adjusted EBITDA Loss Widens To NOK 12.7 Mln

Arctic Bioscience AS

29/04/2024 07:14

April 29 (Reuters) - Arctic Bioscience AS  ABSA.OL :
    * Q1 2024 OPERATIONAL UPDATE - PROGRESS ACCORDING TO PLAN
    * GROSS PROFIT IN Q1 2024 INCREASED TO NOK 1.7 MILLION
    * Q1 ADJUSTED EBITDA: NOK -12,7 MILLION (NOK -12,1 MILLION)
    * Q1 REVENUES FROM SALES: NOK 6,1 MILLION (NOK 7,8 MILLION)
    * IN SECOND HALF OF 2024 WE EXPECT 6 MONTHS PRIMARY END
POINTS
READ-OUT FOR HEROPA-STUDY IN MILD-TO-MODERATE PSORIASIS (HRO350)
    * NUTRACEUTICAL BUSINESS IS EXPECTED TO HAVE A POSITIVE
SALES
GROWTH IN 2024 COMPARED TO PREVIOUS YEARS

Source text for Eikon:  ID:nWkr5p3dhz 
Further company coverage:  ABSA.OL 

 (Gdansk Newsroom)
 ((gdansk.newsroom@thomsonreuters.com; +48 58 7696600;))